Evidence map›Paper›PMID 20706577›Full record

ArticlePloS one2010

Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation.

Anna Murzyn, Anna Krasowska, Piotr Stefanowicz, Dorota Dziadkowiec, Marcin Łukaszewicz

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01411748 (Comparison of Saccharomyces Boulardii and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants), which is not on this map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01411748 phase4unknown statusnot on this mapstarted 2011, after this paper: background citation

Comparison of Saccharomyces Boulardii and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants

TypeinterventionalSponsorZekai Tahir Burak Women's Health Research and Education HospitalRan2011 to 2011Enrolled140ConditionsAnticandidal Property of Saccharomyces Boulardii on Very Low Birth Weight InfantsArmsReflor, mikostatin
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 160 citations in OpenAlex.

  1. Trial
  2. Review
  3. OvercomingFrontiers in antibiotics · 2026
    Review
  4. Application ofIranian journal of microbiology · 2025
    Review
  5. Biotherapeutic Potential of Probiotic YeastIndian journal of microbiology · 2025
    Article
  6. Article
  7. BTS1-knockoutFrontiers in cellular and infection microbiology · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. Anti-Cariogenic Effects ofPharmaceutics · 2024
    Article
  12. Potential probiotic and functional properties ofFrontiers in microbiology · 2024
    Article
  13. SynergisticFrontiers in cellular and infection microbiology · 2024
    Article
  14. Surfactin and Capric Acid Affect the Posaconazole Susceptibility ofInternational journal of molecular sciences · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Fatty Acids AbolishMicrobiology spectrum · 2023
    Article
  20. The Interplay betweenMicroorganisms · 2023
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Anna MurzynFaculty of Biotechnology, University of Wrocław, Wrocław, Poland.
Anna Krasowska
Piotr Stefanowicz
Dorota Dziadkowiec
Marcin Łukaszewicz
University of Wrocław · PLWrocław University of Science and Technology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Candidiasis are life-threatening systemic fungal diseases, especially of gastro intestinal track, skin and mucous membranes lining various body cavities like the nostrils, the mouth, the lips, the eyelids, the ears or the genital area. Due to increasing resistance of candidiasis to existing drugs, it is very important to look for new strategies helping the treatment of such fungal diseases. One promising strategy is the use of the probiotic microorganisms, which when administered in adequate amounts confer a health benefit. Such a probiotic microorganism is yeast Saccharomyces boulardii, a close relative of baker yeast. Saccharomyces boulardii cells and their extract affect the virulence factors of the important human fungal pathogen C. albicans, its hyphae formation, adhesion and biofilm development. Extract prepared from S. boulardii culture filtrate was fractionated and GC-MS analysis showed that the active fraction contained, apart from 2-phenylethanol, caproic, caprylic and capric acid whose presence was confirmed by ESI-MS analysis. Biological activity was tested on C. albicans using extract and pure identified compounds. Our study demonstrated that this probiotic yeast secretes into the medium active compounds reducing candidal virulence factors. The chief compound inhibiting filamentous C. albicans growth comparably to S. boulardii extract was capric acid, which is thus responsible for inhibition of hyphae formation. It also reduced candidal adhesion and biofilm formation, though three times less than the extract, which thus contains other factors suppressing C. albicans adherence. The expression profile of selected genes associated with C. albicans virulence by real-time PCR showed a reduced expression of HWP1, INO1 and CSH1 genes in C. albicans cells treated with capric acid and S. boulardii extract. Hence capric acid secreted by S. boulardii is responsible for inhibition of C. albicans filamentation and partially also adhesion and biofilm formation.

Indexed as

Bacterial AdhesionBiofilmsCandida albicansDecanoic AcidsGene Expression Regulation, FungalHyphaePhenylethyl AlcoholPlasticsSaccharomycesSurface Propertiesdecanoic acidDecanoic AcidsPhenylethyl AlcoholPlastics

Identifiers

PMID20706577
PMCPMC2919387
OpenAlexW2121118426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.